Journal of Preventive Cardiology
Current Issue

Review Article

Year: 2016 I  Volume: 6I  Issue: 1I  Pages:954–961

Dyslipidemia in children and adolescents

Dr. Peeyush Jain*, MBBS, MD (Med), DM (Cardiology); Sitaraman Radhakrishnan†, MBBS, MD (Med),
DM (Cardiology); Dr. Ashok Seth‡, FRCP (London),
FRCP (Edinburgh), FRCP (Ireland), FACC, FESC, FSCAI (USA), FIMSA, FCSI,
D.Sc. (Honoris Causa), D.Litt (Honoris Causa)
*Director (Cardiology) and Head, Department of Preventive Cardiology, Fortis-Escorts Heart Institute, New Delhi, India
†Director, Department of Pediatric and Fetal Cardiology, Fortis-Escorts Heart Institute, New Delhi, India
‡Chairman, Fortis Escorts Heart Institute; Chairman, Cardiology Council, Fortis Group of Hospitals; Past President, Cardiological Society of India; Vice President, Asian Pacific Society of Cardiology, Member, Medical Council of India



Some children have genetically determined dyslipidemias that predisposes them to early heart attacks. In addition, dyslipidemias associated with obesity and diabetes mellitus are being increasingly recognized in children and adolescents. Postponing treatment of severely elevated cholesterol until middle-age or late adulthood in both situations may be too late for some children. It is now recommended that all children should be screened for lipids between ages 9 and 11 years and once again between ages 17 and 21 years. Selective screening in other age groups may be desirable if childhood hypertension, diabetes, or obesity is present. Evaluation for a cause is necessary in children with abnormal lipid levels. Severe elevation is likely to be genetic in origin. The mainstay of treatment of high cholesterol levels in children and adolescents is diet and physical activity. No dietary restriction is recommended below 2 years of age. When cholesterol levels are very high and presumed or known to be genetic, children above 8–10 years of age may benefit from statin therapy; however, the dosing should be conservative. Routine health monitoring should include assessment of growth and development and annual liver functions. Bile acid sequestrants and ezetimibe are also approved for children. For homozygous familial hypercholesterolemia (HoFH), the only therapy available is lipoprotein apheresis (LA). LA is presently not available in India. Recently, US Federal Drug Agency has approved mipomersen and lomitapide aimed at reducing cholesterol in HoFH.

Genetically determined dyslipidemia
Familial hypercholesterolemia
Lipoprotein apheresis
[Full Text]
Print this Article
Back to main page
  • State-of-the-art Article
    Epidemiology of Diabetes Mellitus in India
    -Dr. Benudhar Nath*, MBBS, MD; Dr. Manash P Baruah
    abstract text full text
  • Review Article
    Diabetic Dy slipidemia-a review
    -Prof. (Col) Surender Kumar, Narendra Kotwal,
    abstract text full text
  • Updates on Statins
    full text
  • News and Views
    full text
  • Forthcoming Events
    full text
  • 72nd Annual Conference (2017) of The Association of Physicians of India
    To be held on January 26-29 2017, Mumbai, India
  • Belgian Society of Cardiology 36th Annual Scientific Meeting 2017 (BSC 2017)
    To be held on February 09-10 2017, Brussels
  • Indian Society of Electro cardiology Conference 2017 (ISECON 2017)
    To be held on February 11-12 2017, New Delhi, India
  • 7th World Congress of Diabetes India 2017
    To be held on February 23-26 2017, New Delhi, India
Journal of Preventive Cardiology
Print ISSN: 2249-4308
Online ISSN: 2277-6559
Frequency: Quarterly
Email This
  [ Separate multiple email addresses with commas (Limit is 10). ]